Pharmaceutical in-licensing · MENA

Connecting Tomorrows.

Cross-border licensing between global innovators and MENA markets. We bring proven medicines to new patients, and new growth to the companies that discovered them.

Discuss an asset How we work

Our approach

Two independent partners. One trusted connection.

Every alliance we build has two sides: a company with a medicine worth sharing, and a regional partner with the reach to deliver it. We stand between them with discretion, scientific fluency, a deep network across MENA and more than four decades of pharmaceutical experience, so both sides can move with confidence from first introduction to signed agreement.

What our team brings

Four decades of pharmaceutical leadership, at the table for every deal.

40+
Years in the pharmaceutical industry
BD
Business development and licensing expertise
Commercial
Operations from launch to market leadership
USA
Company established in the United States
Side AGlobal Partner
Side BMENA Partner

The innovator

A proven medicine, robust clinical data and the ambition to reach patients in new markets.

Brings
Asset · Data · IP
From
US · Europe · Asia

The licensee

Regulatory expertise, commercial reach and the trust of health systems across MENA.

Brings
Registration · Access · Reach
In
Twelve MENA markets
Biolink Alliances One alliance. Built on trust.

Services

We represent the partnership, on both sides of the table.

Whether you hold the asset or the market, we find the counterpart who fits, and we build the deal that lasts.

Gloved hand pipetting samples into tubes at a laboratory bench
Discovery01
For global innovators

License your portfolio into MENA.

For pharmaceutical and biotech companies ready to license approved or late-stage products to partners in MENA.

  • Partner searchA qualified shortlist of licensees with the regulatory, commercial and supply capability your product needs.
  • Market assessmentCountry-by-country view of registration pathways, pricing dynamics and launch sequencing.
  • Deal structuringTerm sheets, upfronts, milestones, royalties and supply terms that reflect the real value of the asset.
  • Alliance managementGovernance after signing, so registration and launch stay on schedule.
3D illustration of a monoclonal antibody; hover to see tweezers lifting a segment from a DNA strand
Delivery02
For MENA partners

Bring tomorrow's medicines home.

For regional distributors, manufacturers and licensees building portfolios that change what patients can access.

  • Asset sourcingCurated in-licensing opportunities from innovators in the US, Europe and Asia, matched to your therapeutic focus.
  • Scientific diligenceClear reading of clinical data, regulatory status and competitive position before you commit.
  • NegotiationRepresentation through exclusivity, territory and commercial terms, in the language global partners expect.
  • Portfolio strategyBuilding a pipeline of licensed products that compounds value year after year.
  • Launch excellencePre-launch planning, regulatory submissions and approvals, stakeholder mapping and introductions to key opinion leaders, payers and institutions, so every product launches with momentum.

Process

From first introduction to first patient.

A licensing deal is a sequence of trust. Each step earns the next, and nothing moves forward without both sides ready.

  1. Scope

    We learn the asset or the portfolio need: indication, data, regulatory status and commercial ambition.

    Weeks 1–2

  2. Match

    Confidential outreach to a vetted shortlist of counterparts. Introductions under NDA only.

    Weeks 3–8

  3. Diligence

    Data rooms, capability reviews and site visits, managed so both sides see what they need.

    Weeks 6–12

  4. Negotiate

    Term sheet to definitive agreement, with structure that rewards both partners for success.

    Weeks 10–20

  5. Launch

    Registration, supply and launch planning, with ongoing alliance governance after signing.

    Signing onward

Our conviction

Every breakthrough deserves a market. Every patient deserves the breakthrough.

Markets

One region. Twelve markets. Millions of patients waiting.

The Middle East and North Africa is among the fastest-growing pharmaceutical regions in the world, with governments investing heavily in healthcare access and local manufacturing. We know each authority, each pathway and the partners who navigate them best.

Regional route. In the Gulf states, alongside national filings, products can be registered once through the GCC centralised registration procedure.

  • KSASaudi ArabiaSaudi Food & Drug Authority (SFDA)
  • UAEUnited Arab EmiratesEmirates Drug Establishment (EDE)
  • KWTKuwaitMinistry of Health, Drug & Food Control
  • QATQatarMinistry of Public Health
  • BHRBahrainNational Health Regulatory Authority (NHRA)
  • OMNOmanMinistry of Health, Drug Safety Center
  • EGYEgyptEgyptian Drug Authority (EDA)
  • JORJordanJordan Food & Drug Administration (JFDA)
  • LBNLebanonMinistry of Public Health
  • IRQIraqMinistry of Health
  • MARMoroccoMoroccan Agency of Medicines & Health Products (AMMPS)
  • DZAAlgeriaNational Agency for Pharmaceutical Products (ANPP)

Values

What every alliance rests on.

Trust & Confidentiality

We build relationships based on trust, discretion and respect for confidential information.

Partnership

We bring the right people and organizations together to create mutually valuable opportunities.

Integrity

We act with honesty, transparency and professionalism in every relationship and transaction.

Scientific Credibility

We value knowledge, evidence and a clear understanding of the pharmaceutical industry.

Global Connection

We connect markets, companies and opportunities across borders with a truly international perspective.

Excellence

We are committed to thoughtful communication, careful execution and high-quality outcomes at every stage.

Our mission

To connect global pharmaceutical companies with trusted partners across MENA, facilitating strategic licensing partnerships that bring innovative medicines to new markets and patients.

Our vision

To become a trusted global bridge between pharmaceutical companies and regional partners, expanding access to innovative medicines across MENA and beyond.

Contact

We source the asset. We find the partner. We forge the alliance.

Whichever side of the table you sit on, we bring the other side to you and manage the connection from first introduction to signed agreement. Every conversation is confidential from the first message.

I represent

Sent to info@biolinkalliances.com. All enquiries are treated as confidential.

Email info@biolinkalliances.com Phone +1 (302) 610-2763
Headquarters
30 N Gould St #63127
Sheridan, Wyoming 82801, USA